Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Observational

Parental Technoference and Behavioral-Emotional Development in Early Childhood: A 6-Month Prospective Study

NCT07387133 · tracked via the Priya Life Science Turkey tracker
Phase
Observational
Started
2026-03-01
Last updated
2026-02-04

Condition(s) studied

Parental TechnoferenceChild Behavioral ProblemsEmotional Development in Early Childhood

Study summary

This study aims to examine the relationship between parental technoference (parents' use of smartphones or other digital devices while spending time with their children) and behavioral and emotional development in early childhood.

The study will include parents of children aged 24 to 60 months who attend a pediatric outpatient clinic. At the beginning of the study, parents will complete an online questionnaire that includes questions about their own smartphone screen time, their child's screen exposure, and standardized questionnaires assessing parental technoference and children's behavioral and emotional characteristics.

Six months after the initial assessment, parents will be contacted again to complete a short follow-up questionnaire, including the behavioral and emotional assessment. The study does not involve any medical intervention or experimental treatment. All participation is voluntary, and responses will be collected anonymously.

The findings of this study are expected to contribute to a better understanding of how parental digital device use during daily interactions may be associated with children's emotional and behavioral development in early childhood.

Eligibility

Sex
ALL
Min age
24 Months
Max age
60 Months
Healthy volunteers
Accepted
Inclusion Criteria: * Children aged 24 to 60 months. * Parent or primary caregiver able to read and understand Turkish. * Parent uses a smartphone and can access device-based screen time information. * Ability to complete an online questionnaire. * Provision of written informed consent by the parent or legal guardian. * Availability for a 6-month follow-up assessment. Exclusion Criteria: * Children with severe neurodevelopmental disorders (e.g., autism spectrum disorder, severe intellectual disability, neurometabolic diseases). * Parents unable to reliably complete questionnaires due to cognitive, psychiatric, or language-related limitations. * Parents who do not use a smartphone or cannot access screen time data. * Refusal or inability to provide informed consent. * Inability to be contacted for follow-up assessment.

Primary outcome measure(s)

  • Child Behavioral and Emotional Difficulties (SDQ Total Difficulties Score) — Baseline and 6 months
    Children's behavioral and emotional difficulties will be assessed using the parent-report version of the Strengths and Difficulties Questionnaire (SDQ). The primary outcome is the SDQ Total Difficulties Score measured at baseline and at 6-month follow-up.

Trial sites (1)

FacilityCityRegionStatus
Sancaktepe Prof. Dr. Ilhan Varank Training and Research Hospital Istanbul Turkey (Türkiye)
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07387133 on ClinicalTrials.gov ↗ ← All trials in Turkey